a. Study flow chart of NWAS statistical methods b. Overview of study findings by methodological phase.

<p>^a Logit(p) = α+β_i0x_age+ β_i1x_{year of diagnosis} + β_i2x_{neighborhood variable (i, j)} + ε_ij;</p> <p>where i = individual cancer cases; j = census tracts (Phase 1)</p> <p>^b Logit(p) = α+β_i0x_age+β_i1x_{year of diagnosis}+β₂x_{neighborhood variable (i, j)} +V_(j) +U_(j)</p> <p>where i = individual prostate cancer cases; j = county, V_{<b><i>(j)</i></b>} are independent non-spatial random effects and U_(j) are spatially structured random effects (Phase 2).</p> <p>*These 17 components explain 90% of the variance</p

Summary of neighborhood variable “top hits” associated with aggressive prostate cancer by phase.

<p>^aStandard deviation (sd); ^bConfidence or Credible Interval (CI).</p

Laboratory Methods Evaluation Comparing Telomere Length by Telomere Assay Type, Center, and DNA extraction method.

<p><b>a-c</b>. Comparison of Log-transformed telomere length (LogTRF) from Southern Blot (also known as terminal restriction fragment (TRF) assays) to log-transformed telomere content (T) to standard gene (S) ratios (Log T/S ratio) from quantitative PCR in the overall sample (<b>a</b>) and by center (<b>b,c</b>; where b = University of Pennsylvania (Penn); c = Ohio State University(OSU)). <b>d</b>. Median telomere length from terminal restriction fragment assays and correlation or R² by DNA extraction method.</p

Additional file 1: Table S1. of Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women

Ethics committees that granted approval for the access and use of the data for this study. Table S2. Participant counts by center and mutation. Table S3. Primers used for PCR and Sanger sequencing. Table S4. Primers used in micro-satellite analysis for loss of heterozygosity. Table S5. Micro-satellite loss of heterozygosity and sequencing analysis results. (DOC 177 kb